Who Generates Higher Gross Profit? Corcept Therapeutics Incorporated or Taro Pharmaceutical Industries Ltd.

Corcept's Growth Outpaces Taro's Decline in Gross Profit

__timestampCorcept Therapeutics IncorporatedTaro Pharmaceutical Industries Ltd.
Wednesday, January 1, 201425669000580006000
Thursday, January 1, 201548925000676585000
Friday, January 1, 201679263000778966000
Sunday, January 1, 2017155647000671251000
Monday, January 1, 2018246032000463508000
Tuesday, January 1, 2019300982000445724000
Wednesday, January 1, 2020348292000399725000
Friday, January 1, 2021360697000296656000
Saturday, January 1, 2022396473000293122000
Sunday, January 1, 2023475894000268323000
Monday, January 1, 2024304979000
Loading chart...

Unleashing insights

Comparing Gross Profit: Corcept Therapeutics vs. Taro Pharmaceutical

In the competitive landscape of pharmaceuticals, understanding which companies lead in profitability is crucial. From 2014 to 2023, Taro Pharmaceutical Industries Ltd. consistently outperformed Corcept Therapeutics Incorporated in terms of gross profit. Taro's gross profit peaked in 2016, reaching nearly 780 million, while Corcept's highest was approximately 476 million in 2023. However, Corcept has shown remarkable growth, with its gross profit increasing by over 1,750% from 2014 to 2023. In contrast, Taro's gross profit declined by about 54% over the same period. This shift highlights Corcept's aggressive growth strategy and Taro's challenges in maintaining its earlier momentum. The data for 2024 is incomplete, but the trends suggest a potential narrowing of the gap between these two industry players. Investors and analysts should watch these trends closely as they may indicate future shifts in market leadership.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025